课题基金 / 基金详情

The impact of myostatin on breast cancer and multiple myeloma bone metastases

The impact of myostatin on breast cancer and multiple myeloma bone metastases
肌肉生长抑制素对乳腺癌和多发性骨髓瘤骨转移的影响
批准号:
401133176
负责人:
Dr. Berno Dankbar, Ph.D.
金额:
$0.0万
依托单位国家:
德国
项目类别:
Priority Programmes
财政年份:
2018
资助国家:
德国
项目状态:
已结题
起止时间:
2017-12-31 至 2021-12-31

项目摘要

项目成果

Dr. Berno Dankbar, Ph.D.的其他基金

相似基金

相关文献

中文摘要
翻译
骨骼中癌症的生长与对骨骼的严重影响有关,并导致相当高的发病率和死亡率。乳腺癌(BC)和多发性(MM)衍生的骨转移都是溶解性的,转移的产生是由成熟破骨细胞的形成和激活介导的。肿瘤细胞与骨微环境之间存在复杂的串扰,为癌细胞提供多种生长因子和破骨因子。在这方面,TGFß家族成员TGFß或激活素A的抑制抑制了MM和BC小鼠模型中的破骨细胞骨吸收,表明这些因素在骨转移形成中的重要作用。在这种情况下,我们最近发现,肌生长抑制素(TGFß家族的另一成员)强烈地促进破骨细胞的发育,并且肌生长抑制素的缺乏或抑制极大地改善了疾病的严重程度,特别是关节炎小鼠的骨侵蚀。有趣的是,初步实验显示myostatin和动作a之间具有高度的相似性。我们可以证明,myostatin和激活素a对rankl诱导的破骨细胞形成的增强程度相同,这表明这两个因子是等效的破骨细胞发育促进因子。此外,这两个因子通过相似的smad通路(Smad2/3)起作用,指出了破骨细胞分化的共同机制。除了这种相似性,其他证据表明肌肉生长抑制素在骨转移中的作用:肌生长抑制素在乳腺癌细胞中表达。ActRII是激活素和肌肉生长抑制素共有的受体类型,在乳腺癌和骨髓瘤细胞中表达。较高水平的磷酸化SMAD2存在于人类BC骨转移中。我们假设,肌生长抑制素参与肿瘤细胞与骨微环境的相互作用,促进破骨细胞的发育,从而促进骨病变,抑制肌生长抑制素可减少骨转移。为此,我们将用抗肌生长抑制素抗体治疗BC和MM的两个同质模型和两个异种移植模型,并评估骨转移的形成。此外,将研究肌生长抑制素在细胞间相互作用中的作用,并测试肿瘤细胞对破骨细胞分化和活性的直接/间接影响。此外,假设肌肉生长抑制素和激活素A都参与骨转移,同时抑制肌肉生长抑制素和激活素A可能为治疗BC和MM的骨转移提供有力的工具。一种能够结合和拮抗肌肉生长抑制素和激活素的蛋白质是一种天然存在的拮抗剂,称为卵泡抑素相关基因(FLRG)。在初步实验中,我们可以证明FLRG完全消除了rankl诱导的破骨细胞形成,无论是由肌肉生长抑制素还是激活素刺激。因此,我们建议在BC和MM小鼠的疾病过程中也用重组FLRG治疗,并如上所述进行分析。
英文摘要
The growth of cancers in the skeleton is associated with severe effects on bone and results in considerable morbidity and mortality. Both, breast cancer (BC) as well as multiple multiple (MM)-derived bone metastases are osteolytic and generation of metastases is mediated by the formation and activation of mature osteoclasts.There is a complex crosstalk between tumor cells and the bone microenvironment providing a variety of growth factors for cancer cells and osteoclastic factors. In this regard inhibition of TGFß or activin A, both members of the TGFß familiy, suppress osteoclastic bone resorption in mouse models of MM and BC, indicating an important role of these factors in the formation of bone metastases.In this context, we have recently discovered that myostatin, another member of the TGFß family, strongly enhances osteoclast development and that deficiency or inhibition of myostatin highly ameliorates disease severity and in particular bone erosion in arthritic mice. Interestingly, preliminary experiments revealed a high similarity between mystatin and action A. We could show that myostatin and activin A enhance RANKL-induced osteoclast formation to the same extent, indicating that both factors are equivalent promoters of osteoclast development. Moreover, both factors act via similar Smad-pathways (Smad2/3), pointing to a common mechanism in osteoclast differentiation. Beside this similarity, additional lines of evidence suggest a role for myostatin in bone metastases: 1. Myostatin is expressed in breast cancer cells, 2. ActRII, the receptor type shared by activin and myostatin, is expressed by breast cancer and myeloma cells, 3. Higher levels of phosphorylated SMAD2 are present in human BC bone metastatases.We hypothesize, that myostatin participates in the interactions of tumor cells with the bone microenvironment, promoting osteoclast development and thereby bone lesions and that inhibition of myostatin reduce bone metastases.For this purpose, we will treat two syngeneic and two xenograft models for both BC and MM with anti-myostatin antibody and assess the formation of bone metastases. Moreover, the role of myostatin in cell-cell interaction will be investigated and direct/ indirect effects of tumor cells on osteoclast differentiation and activity will be tested. Furthermore, assuming that both myostatin and activin A are involved in bone metastases, inhibiting myostatin and activin A simultaneously may provide a powerful tool for the treatment of bone metastases in BC and MM. A protein which is able to bind and antagonize myostatin as well as activin is a natural occuring antagonist called „Follistatin-related gene“ (FLRG). In preliminary experiments, we could demonstrate that FLRG completely abrogates RANKL-induced osteoclast formation either stimulated with myostatin and activin. We therefore proposed to treat BC and MM mice also with recombinant FLRG in the course of the disease and analysed as described above.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The role of myostatin in joint destruction in rheumatoid arthritis
  • 批准号:
    169271848
  • 项目类别:
    Priority Programmes
  • 资助金额:
    $0.0万
  • 财政年份:
    2010
  • 负责人:
    Dr. Berno Dankbar, Ph.D.
  • 依托单位:
The protective function of the Wnt inhibitor sclerostin in inflammatory bone destruction.
  • 批准号:
    159725117
  • 项目类别:
    Research Grants
  • 资助金额:
    $0.0万
  • 财政年份:
    2009
  • 负责人:
    Dr. Berno Dankbar, Ph.D.
  • 依托单位:
Maligne Knochentumore: Modulation von Apoptose und Invasion durch den Gewebeinhibitor von Metalloproteinasen-3 (TIMP-3)
Krankheitsspezifische Induktion der Serinprotease FAP in der rheumatoiden Arthritis: Funktion und Regulation bei der osteoklastären Knochendestruktion.
国内基金
海外基金
基于Myostatin-Akirin1介导的肌卫星细胞功能探明肾衰营养胶囊对CKD-PEW骨骼肌萎缩的作用机制
  • 批准号:
    82305168
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘玲玉
  • 依托单位:
GASP-1通过Myostatin信号通路调控颏舌肌功能的作用及机制研究
  • 批准号:
    82371131
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    易红良
  • 依托单位:
基于Sirt6/NF-κB/Myostatin信号通路探讨女贞子抗肌少-骨质疏松症的分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    51万元
  • 批准年份:
    2022
  • 负责人:
    张东伟
  • 依托单位:
抑肌素(myostatin)在青鲫肌肉发育调控网络中的角色和功能研究
  • 批准号:
    32172965
  • 项目类别:
    面上项目
  • 资助金额:
    58万元
  • 批准年份:
    2021
  • 负责人:
    张运生
  • 依托单位: